Results 231 to 240 of about 32,467 (248)

A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context

International Journal of Antimicrobial Agents, 2004
Gemifloxacin is a broad-spectrum quinolone antibacterial with enhanced potency against Gram-positive bacteria, including multi-drug resistant Streptococcus pneumoniae, and retained potency against Gram-negative bacilli and bacterial strains resistant to other antibiotics.
P, Ball, L, Mandell, G, Patou, W, Dankner, G, Tillotson   +4 more
openaire   +2 more sources

A Critical Review of the Fluoroquinolones

Drugs, 2002
The new fluoroquinolones (clinafloxacin, gatifloxacin, gemifloxacin, grepafloxacin, levofloxacin, moxifloxacin, sitafloxacin, sparfloxacin and trovafloxacin) offer excellent activity against Gram-negative bacilli and improved Gram-positive activity (e.g. against Streptococcus pneumoniae and Staphylococcus aureus) over ciprofloxacin. Ciprofloxacin still
George G, Zhanel, Kelly, Ennis, Lavern, Vercaigne, Andrew, Walkty, Alfred S, Gin, John, Embil, Heather, Smith, Daryl J, Hoban   +7 more
openaire   +2 more sources

Fluoroquinolones in respiratory infections.

Seminars in respiratory infections, 1992
The fluoroquinolones have excellent activity against a number of respiratory pathogens, especially gram-negative bacteria, including beta-lactamase-producing Hemophilus influenzae and Moraxella catarrhalis. Several studies have shown ciprofloxacin to be effective in the treatment of acute exacerbations of chronic bronchitis, some community-acquired and
openaire   +1 more source

Comparative penetration of selected fluoroquinolones into respiratory tract fluids and tissues

The American Journal of Medicine, 1991
Sputum samples are easy to obtain; however, their use in therapeutic decision making is not without problems. Today, with the availability of more sophisticated endoscopic procedures, it is possible to determine antimicrobial concentrations at various sites within the respiratory tract.
openaire   +2 more sources

Role of fluoroquinolones in lower respiratory tract infections.

Clinical and investigative medicine. Medecine clinique et experimentale, 1989
Oral quinolones such as ciprofloxacin are promising agents in the treatment of serious bronchopulmonary infections due to susceptible gram-negative micro-organisms such as Haemophilus influenzae, Branhamella catarrhalis, Klebsiella pneumoniae and even Pseudomonas aeruginosa.
openaire   +1 more source

[Role of oral fluoroquinolones in patients with respiratory diseases].

Kekkaku : [Tuberculosis], 2004
The characteristics of recently developed oral fluoroquinolones include their broad spectrum involving gram-positive/gram-negative bacteria and atypical pathogens, potent antimicrobial activity against Pneumococcus, rapid tissue/sputum transfer, prolonged half-life, and reduction of their interaction with other agents.
openaire   +1 more source

Fluoroquinolones for Respiratory Infections

Chest, 2001
openaire   +1 more source

FLUOROQUINOLONES AND RESPIRATORY TRACT INFECTIONS

Infectious Diseases in Clinical Practice, 1997
openaire   +1 more source

Fluoroquinolones and lower respiratory tract infections

2004
A. Kuhnke, H. Lode
openaire   +1 more source

[Levofloxacin and other fluoroquinolones in therapy of respiratory tract infections].

Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2011
Levofloxacin, like other fluoroquinolones, acts as a antibacterial agent on bacterial topoisomerases. A broad range of Gram-positive and Gram-negative of levofloxacin was confirmed in clinical trials in patients with respiratory tract infections.
openaire   +1 more source